Lab-Grown Mini-Hearts Could Revolutionize Drug Safety Testing

Scientists from the Fraunhofer Institute and Hannover Medical School have created a mini-heart organoid to study drug side effects. The tiny, lab-grown structures can beat on their own and mimic human heart tissue. They offer a new way to test how medications affect the heart before human trials begin. The organoids contain four key cell types: heart muscle cells, cardiac fibroblasts, endothelial cells, and mesenchymal stem cells. All are derived from induced pluripotent stem cells (hiPSCs), allowing them to closely resemble human heart tissue. Their spontaneous beating can be controlled with electrical pulses, making them useful for detailed analysis.

Researchers can study the organoids' contractions, examine their structure under a microscope, and analyse gene activity at a single-cell level. This helps identify whether new drugs cause harmful effects like irregular rhythms or muscle damage. The team demonstrated that the organoids respond to drugs such as mavacamten, which alters heart muscle contraction. The organoids remain viable for at least thirty days, enabling long-term experiments. This extended lifespan makes them particularly useful for testing novel treatments, including RNA-based therapies. To further improve the model, the team is now working to add immune cells—macrophages derived from the same stem cells. This addition would make the organoids even more similar to a real human heart, improving the accuracy of drug tests.

The new organoid model could speed up drug development by providing a reliable way to screen for cardiotoxicity early in the process. It reduces the need for costly and time-consuming animal or human trials. Future versions with immune cells may bring research even closer to real-world conditions.